Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expands By 159.9%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 5,120,000 shares, agrowthof159.9% from the June 30th total of 1,970,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is presently 3.3 days. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is presently 3.3 days.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.43 on Monday. The business's 50-day moving average is $1.72 and its two-hundred day moving average is $1.62. The company has a market capitalization of $76.45 million, a P/E ratio of -1.83 and a beta of 0.52. The company has a debt-to-equity ratio of 4.06, a quick ratio of 4.67 and a current ratio of 4.67. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). Research analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target on the stock in a research report on Thursday, June 5th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $7.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. National Bank of Canada FI boosted its stake in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after acquiring an additional 11,600 shares in the last quarter. Bay Rivers Group purchased a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter worth about $28,000. XTX Topco Ltd boosted its stake in shares of Milestone Pharmaceuticals by 52.7% during the 1st quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after acquiring an additional 17,950 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after acquiring an additional 30,772 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth about $73,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.